Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
N Engl J Med
    October 2025
  1. RUDIN CM, Mountzios G
    Tarlatamab in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2025;393:1348-1349.
    >> Share

  2. YILDIZ O, Araz M
    Tarlatamab in Small-Cell Lung Cancer.
    N Engl J Med. 2025;393:1348.
    >> Share

    August 2025
  3. CALVO V
    Redefining Lung Cancer Therapy - A Long-Awaited Shift in Strategy.
    N Engl J Med. 2025;393:809-810.
    >> Share

    June 2025
  4. LENTZ RJ, Frederick-Dyer K, Planz VB, Koyama T, et al
    Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
    N Engl J Med. 2025;392:2100-2112.
    >> Share

  5. MOUNTZIOS G, Sun L, Cho BC, Demirci U, et al
    Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502099.
    >> Share

  6. FORDE PM, Spicer JD, Provencio M, Mitsudomi T, et al
    Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931.
    >> Share

    April 2025
  7. HEYMACH JV, Ruiter G, Ahn MJ, Girard N, et al
    Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2025 Apr 28. doi: 10.1056/NEJMoa2503704.
    >> Share

  8. PICH O, Bernard E, Zagorulya M, Rowan A, et al
    Tumor-Infiltrating Clonal Hematopoiesis.
    N Engl J Med. 2025;392:1594-1608.
    >> Share

    December 2024
  9. SENAN S
    Durvalumab in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;391:2386.
    >> Share

  10. PETRELLI F, Dottorini L, Ghidini A
    Durvalumab in Small-Cell Lung Cancer.
    N Engl J Med. 2024;391:2385-2386.
    >> Share

  11. RAMELLA S, Ippolito E, D'Angelillo RM
    Durvalumab in Small-Cell Lung Cancer.
    N Engl J Med. 2024;391:2385.
    >> Share

    October 2024
  12. CHO BC, Lu S, Felip E, Spira AI, et al
    Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2024;391:1486-1498.
    >> Share

    September 2024
  13. CHENG Y, Spigel DR, Cho BC, Laktionov KK, et al
    Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
    N Engl J Med. 2024 Sep 13. doi: 10.1056/NEJMoa2404873.
    >> Share

  14. WITTROCK E, Hagner MD
    Cannonball Pulmonary Lesions.
    N Engl J Med. 2024;391:844.
    >> Share

    August 2024
  15. LEIGHL NB
    Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match.
    N Engl J Med. 2024;391:652-654.
    >> Share

  16. LU S, Kato T, Dong X, Ahn MJ, et al
    Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
    N Engl J Med. 2024;391:585-597.
    >> Share

  17. CASCONE T, Spicer JD, Provencio Pulla M
    Perioperative Nivolumab in Resectable Lung Cancer. Reply.
    N Engl J Med. 2024;391:573-574.
    >> Share

  18. SORSCHER S
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:573.
    >> Share

  19. SOBRERO S, Vaisitti F, Leo F
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:572-573.
    >> Share

    June 2024
  20. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    >> Share

    May 2024
  21. GARASSINO MC, Torri V
    Neoadjuvant or Perioperative Approach in Lung Cancer.
    N Engl J Med. 2024;390:1816-1818.
    >> Share

  22. CASCONE T, Awad MM, Spicer JD, He J, et al
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;390:1756-1769.
    >> Share

    April 2024
  23. PASSARO A, Peters S
    Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
    N Engl J Med. 2024;390:1325-1327.
    >> Share

  24. WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al
    Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:1265-1276.
    >> Share

  25. IZZEDINE H, Bouderlique E, Besse B
    Selpercatinib and Pseudo-Decreases in Kidney Function.
    N Engl J Med. 2024;390:1241-1243.
    >> Share

    February 2024
  26. ZHOU C, Agrawal T, Girard N
    VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
    N Engl J Med. 2024;390:579-580.
    >> Share

  27. MOIK F, Riedl JM, Ay C
    VTE with Amivantamab plus Chemotherapy in NSCLC.
    N Engl J Med. 2024;390:578-579.
    >> Share

  28. PLANCHARD D, Janne PA, Kobayashi K
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2024;390:478-479.
    >> Share

  29. VAN WAALWIJK VAN DOORN-KHOSROV, Badrising SK, Burgers S
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    N Engl J Med. 2024;390:478.
    >> Share

    January 2024
  30. HEYMACH JV, Harpole D, Reck M
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;390:287-288.
    >> Share

  31. HORITA N, Fujiwara Y
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:287.
    >> Share

  32. DRILON A, Camidge DR, Lin JJ, Kim SW, et al
    Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:118-131.
    >> Share

    November 2023
  33. ZHOU C, Tang KJ, Cho BC, Liu B, et al
    Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
    N Engl J Med. 2023;389:2039-2051.
    >> Share

  34. PLANCHARD D, Janne PA, Cheng Y, Yang JC, et al
    Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2023;389:1935-1948.
    >> Share

  35. MULLIGAN L
    Selective RET Kinase Inhibitors and Lung Cancer.
    N Engl J Med. 2023;389:1913-1916.
    >> Share

  36. MCCANNON JB, Shepard JO, Wong AK, Thomas MF, et al
    Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.
    N Engl J Med. 2023;389:1902-1911.
    >> Share

  37. ZHOU C, Solomon B, Loong HH, Park K, et al
    First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
    N Engl J Med. 2023;389:1839-1850.
    >> Share

  38. WU YL, Zhou Q
    Combination Therapy for EGFR-Mutated Lung Cancer.
    N Engl J Med. 2023 Nov 8. doi: 10.1056/NEJMe2311559.
    >> Share

    October 2023
  39. HEYMACH JV, Harpole D, Mitsudomi T, Taube JM, et al
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 23. doi: 10.1056/NEJMoa2304875.
    >> Share

  40. AHN MJ, Cho BC, Felip E, Korantzis I, et al
    Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980.
    >> Share

  41. PROVENCIO M, Massuti B, Romero A
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;389:1534-1535.
    >> Share

  42. VERMA S, Vincent M, Breadner D
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;389:1534.
    >> Share

  43. TSUBOI M, Herbst RS, Wu YL
    Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2023;389:1342.
    >> Share

  44. DI MAIO M
    Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023;389:1341-1342.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016